Background
Methods
Serum 25-hydroxyvitamin D
Statistical analysis
Results
Females1
| 18 (45) |
Age (years)2
| 11 ± 4.23 |
Subtype of JIA1
| |
Systemic-onset arthritis | 11 (27.5) |
Oligoarthritis | 9 (22.5) |
Rheumatoid factor- positive polyarthritis | 17 (45.5) |
Rheumatoid factor- negative polyarthritis | 1 (2.5) |
Enthesitis-related arthritis | 1 (2.5) |
Psoriatic arthritis | 1 (2.5) |
Time since JIA onset (years)3
| 2 [1–5] |
Medications used1
| |
NSAID | 30 (75) |
Corticosteroid | 23 (57.5) |
Methotrexate | 16 (40) |
sulfassalazine | 6 (15) |
Biologics | 3 (7.5) |
Ciclosporin | 1 (2.5) |
CHAQ3
| 0.5 [0–1.75] |
Tender joints1
| 3 [1–8] |
Swollen joints1
| 1 [0–3] |
ESR (mm/h)1
| 34.5 [25–55] |
CRP (mg/l)1
| 21.5 [11–41] |
Patient global assessment (cm)1
| 25 [10–40] |
DAS282
| 4.84 ± 1.27 |
BASDAI1
| 1.4 [0–2.6] |
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
β | CI | p | β | CI | p | |
Age (years) | −0. 32 | (−1.15, 0.51) | 0.4 | |||
BMI | −0.15 | (−0.96, 0.65) | 0.7 | |||
Time since JIA onset (years) | −0.52 | (−1.74, 0.69) | 0.4 | |||
JIA subtype | ||||||
Oligoarthritis | 0 | |||||
Systemic-onset arthritis | −0.92 | (−8.81, 6.96) | 0.8 | |||
Polyarticular forms | −0.55 | (−7.61, 6.50) | 0.8 | |||
CHAQ | −3.28 | (−7.31, 0.75) | 0.1 | |||
Patient global health (cm) | −0.17 | (−0.35, −0.004) |
0.04
| −0.6 | (−0.50, 0.38) | 0.7 |
Tender joints | −0.79 | (−1.47, −0.10) |
0.02
| −1.23 | (−3.76, 1.30) | 0.3 |
Swollen joints | −0.67 | (−1.78, 0.42) | 0.2 | |||
ESR (mm/h) | −0.14 | (−0.28, 0.004) |
0.05
| −0.21 | (−0.66, 0.23) | 0.3 |
DAS28 | −3.87 | (−7.67, −0.07) |
0.04
| 4.02 | (−0.66, 0.23) | 0.6 |
BASDAI | −1.88 | (−6.40, 2.62) | 0.3 | |||
Medications used: | ||||||
NSAID | 1.45 | (−6.67, 9.57) | 0.7 | |||
Corticosteroid | 1.08 | (−6.04, 8.2) | 0.7 | |||
Methotrexate | −3.63 | (−10.73, 3.46) | 0.3 | |||
Sulfassalazine | −0.04 | (−9.91, 9.83) | 0.9 | |||
Biologics | 1.56 | (−11.81, 14.94) | 0.81 |